This “Follicular Lymphoma- Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Follicular lymphoma (FL) is typically a slow-growing or indolent form of non- Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. Common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. Often, patients with FL have no obvious symptoms of the disease at diagnosis. Follicular lymphoma is usually not considered to be curable, but more of a chronic disease. Patients can live for many years with this form of lymphoma. Follicular lymphoma is a B-cell lymphoma. It is characterized by the transformation of a B-cell into a malignant (cancerous) cell. Abnormal, uncontrolled growth and multiplication (proliferation) of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs. The term follicular lymphoma comes from the observation that the cancer cells are group in clusters (or follicles) within the lymph nodes. Non-Hodgkin lymphoma including follicular lymphoma can be characterized as “low-grade” (or indolent), meaning the cancer tends to grow slowly and results in few associated symptoms or “high-grade” (aggressive), meaning the cancer typically grows rapidly. The exact, underlying cause of follicular lymphoma is not fully understood. The reason why cancer develops is a complex question and researchers speculate that multiple factors are involved in the development of follicular lymphoma. These factors include genetic, environmental and immunologic factors, which all may play a role in the development of this cancer.
"Follicular Lymphoma- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular Lymphoma pipeline landscape is provided which includes the disease overview and Follicular Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pembrolizumab: Merck & Co
Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body's own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.
This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genetech.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular Lymphoma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular Lymphoma drugs.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Follicular Lymphoma: Understanding
Follicular Lymphoma: Overview
Follicular lymphoma (FL) is typically a slow-growing or indolent form of non- Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. Common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. Often, patients with FL have no obvious symptoms of the disease at diagnosis. Follicular lymphoma is usually not considered to be curable, but more of a chronic disease. Patients can live for many years with this form of lymphoma. Follicular lymphoma is a B-cell lymphoma. It is characterized by the transformation of a B-cell into a malignant (cancerous) cell. Abnormal, uncontrolled growth and multiplication (proliferation) of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs. The term follicular lymphoma comes from the observation that the cancer cells are group in clusters (or follicles) within the lymph nodes. Non-Hodgkin lymphoma including follicular lymphoma can be characterized as “low-grade” (or indolent), meaning the cancer tends to grow slowly and results in few associated symptoms or “high-grade” (aggressive), meaning the cancer typically grows rapidly. The exact, underlying cause of follicular lymphoma is not fully understood. The reason why cancer develops is a complex question and researchers speculate that multiple factors are involved in the development of follicular lymphoma. These factors include genetic, environmental and immunologic factors, which all may play a role in the development of this cancer.
"Follicular Lymphoma- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular Lymphoma pipeline landscape is provided which includes the disease overview and Follicular Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular Lymphoma.
Follicular Lymphoma Emerging Drugs Chapters
This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular Lymphoma Emerging Drugs
- Mosunetuzumab - Genentech
- Tafasitamab - Incyte Corporation
Pembrolizumab: Merck & Co
Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body's own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.
- Zanubrutinib - BeiGene
Follicular Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Follicular Lymphoma
There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genetech.
Phases
This report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Follicular Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular Lymphoma drugs.
Follicular Lymphoma Report Insights
- Follicular Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Follicular Lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Follicular Lymphoma drugs?
- How many Follicular Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular Lymphoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Follicular Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Merck & Co
- Genentech
- Incyte Corporation
- Syndax Pharmaceuticals
- Dr Reddy's Laboratories
- Novartis
- ADC Therapeutics
- Xynomic Pharmaceuticals
- Cho Pharma Inc.
- Janssen
- XEME Biopharma Inc.
- Shanghai Yingli Pharmaceutical
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd.
- Archigen Biotech
- Hutchison Medipharma Limited
- Nordic Nanovector
- Xynomic Pharmaceuticals
- TG Therapeutics
- BeiGene
- Allogene Therapeutics
- MEI Pharma, Inc.
- Pfizer
- Innovent Biologics (Suzhou) Co. Ltd.
- Enterome
- AstraZeneca
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Takeda
- Bristol-Myers Squibb
- TCR2 Therapeutics
Key Products
- Pembrolizumab
- Mosunetuzumab
- Tafasitamab
- Entinostat
- DRL_RI
- Tisagenlecleucel
- Loncastuximab Tesirine
- Abexinostat
- CHO-H01
- Ibrutinib
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
Follicular Lymphoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Follicular Lymphoma- Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
Drugname: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Follicular Lymphoma Key Companies
Follicular Lymphoma Key Products
Follicular Lymphoma- Unmet Needs
Follicular Lymphoma- Market Drivers and Barriers
Follicular Lymphoma- Future Perspectives and Conclusion
Follicular Lymphoma Analyst Views
Follicular Lymphoma Key Companies
Appendix
*The Table of Contents is not exhaustive; will be provided in the final reportList of Tables
Table 1 Total Products for Follicular Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Follicular Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Merck & Co
- Genentech
- Incyte Corporation
- Syndax Pharmaceuticals
- Dr Reddy's Laboratories
- Novartis
- ADC Therapeutics
- Xynomic Pharmaceuticals
- Cho Pharma Inc.
- Janssen
- XEME Biopharma Inc.
- Shanghai Yingli Pharmaceutical
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd.
- Archigen Biotech
- Hutchison Medipharma Limited
- Nordic Nanovector
- Xynomic Pharmaceuticals
- TG Therapeutics
- BeiGene
- Allogene Therapeutics
- MEI Pharma, Inc.
- Pfizer
- Innovent Biologics (Suzhou) Co. Ltd.
- Enterome
- AstraZeneca
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Takeda
- Bristol-Myers Squibb
- TCR2 Therapeutics